Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Q2 results

- PMLiVE

Lundbeck’s key products shine in Q2 but problems remain

Faces increasing patent losses

- PMLiVE

Boehringer posts solid first half as business revamp beds in

Jardiance helped to boost sales

Biomarin

BioMarin ticks over in Q2 ahead of gene therapy filing

Haemophilia candidate valrox will be a game-changer for company

- PMLiVE

Leiden reassures on key role at Vertex

Reshma Kewalramani to be new CEO, but Leiden will retain portfolio

- PMLiVE

Keytruda scores in neoadjuvant triple negative breast cancer combo

Tecentriq still in pole position

- PMLiVE

Dupixent drives Sanofi again, but other new drugs are lagging

Reported loss due to restructuring

Roche Basel Switzerland

New products help lift Roche outlook despite biosimilar onslaught

Two new cancer therapies approved in Q2

- PMLiVE

Pharma fears “lack of focus” on no-deal Brexit preparations

As Brexit is delayed, pharma suggests new measures to avoid no-deal drugs shortages

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

- PMLiVE

GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

Partners to co-develop novel bifunctional fusion protein

- PMLiVE

Tackling a formidable foe

Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis

- PMLiVE

Immuno-oncology at ASCO: survival data, combinations and new indications

The abstracts reveal heaps of strong contenders in the NSCLC category

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links